NASDAQ:IBRX ImmunityBio Q3 2026 Earnings Date & Estimates $8.93 +0.64 (+7.72%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$8.83 -0.10 (-1.16%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ImmunityBio is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ImmunityBio in Q3 2026ImmunityBio is expected to post earnings of -$0.07 per share on revenue of $59.23 million. In the same quarter a year earlier ImmunityBio reported -$0.0711 per share on revenue of $32.06 million. ImmunityBio last reported on August 4, 2026, posting -$0.22 per share and missing the -$0.08 consensus estimate. ImmunityBio has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.07Expected Revenue$59.23 millionPrior-Year EPS-$0.0711Prior-Year Revenue$32.06 millionExpected Revenue Growth+84.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.22 (Missed by -$0.14)Last Quarter Revenue$51.24 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report ImmunityBio Q3 2026 Earnings FAQ When does ImmunityBio report Q3 2026 earnings? ImmunityBio (NASDAQ:IBRX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is ImmunityBio's Q3 2026 earnings call? ImmunityBio's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ImmunityBio? Analysts expect ImmunityBio to post earnings of -$0.07 per share for Q3 2026. How much revenue is ImmunityBio expected to report? The consensus revenue estimate for ImmunityBio is $59.23 million for Q3 2026. ImmunityBio Earnings HeadlinesImmunityBio Treats First Patients in Europe With Anktiva for Invasive Bladder CancerNovember 4 at 6:11 PM | marketscreener.comMImmunityBio Treats First Patients in Europe With Anktiva for Invasive Bladder CancerNovember 4 at 6:11 PM | marketscreener.comMThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one recent month, those payments added up to $1,127, without the risks of management decisions or rising mining costs.November 5 at 1:00 AM | Investors Alley (Ad)ImmunityBio treats first patients in Europe with Anktiva plus BCG – retail calls it a great opening act for Q3 earningsNovember 4 at 6:11 PM | msn.comImmunityBio treats first patients in Europe with Anktiva plus BCG – retail calls it a great opening act for Q3 earningsNovember 4 at 6:11 PM | msn.comDoes ImmunityBio (IBRX) Look Fully Priced After A 310% Jump?November 4 at 6:11 PM | finance.yahoo.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process. Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In the United States, Anktiva is approved for use with Bacillus Calmette-Guérin in certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating Anktiva and related therapies in additional cancer indications and treatment combinations. The company’s broader pipeline includes investigational therapies intended to support cancer immunotherapy, cellular immune responses and vaccine development. ImmunityBio was formed through the combination of ImmunityBio and NantKwest, completed in 2021, bringing together complementary immunotherapy platforms. The company is headquartered in California and was founded by Patrick Soon-Shiong, who serves as its executive chairman and has played a central role in its scientific and corporate direction.View ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it Simple Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
